Tag: OCEANIC-AF

Bayer Announces First Patients Enrolled in Global Phase III Studies for Investigational Oral FXIa Inhibitor Asundexian

The OCEANIC program will investigate the efficacy and safety of asundexian (BAY2433334) in the prevention of stroke in patients with atrial fibrillation and also patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA)1,2 OCEANIC-AF and OCEANIC-STROKE are expected to enroll more than 27,000 patients in over 40 countries 3 February 08, 2023 07:00 […]

Bayer Initiates Phase III Study Program for Investigational Oral FXIa Inhibitor Asundexian

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in the prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack1,2 OCEANIC-AF and OCEANIC-STROKE are expected to enroll up to 30,000 patients in over […]